Halozyme Therapeutics Inc. (HALO) Trading Down 3.1%
Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) fell 3.1% during trading on Tuesday . The stock traded as low as $9.95 and last traded at $10.09, with a volume of 567,384 shares traded. The stock had previously closed at $10.41.
Several research firms have commented on HALO. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Canaccord Genuity reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Jefferies Group reaffirmed a “sell” rating and issued a $6.75 target price on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $15.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, June 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Halozyme Therapeutics has an average rating of “Buy” and a consensus target price of $15.68.
The firm’s 50-day moving average is $9.46 and its 200-day moving average is $9.37. The firm’s market cap is $1.27 billion.
Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. The business had revenue of $33.30 million for the quarter, compared to analyst estimates of $29.94 million. During the same period in the prior year, the company earned $0.02 earnings per share. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis. Equities research analysts forecast that Halozyme Therapeutics Inc. will post ($0.91) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Halozyme Therapeutics stock. California Public Employees Retirement System raised its stake in shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 255,600 shares of the biopharmaceutical company’s stock after buying an additional 23,600 shares during the period. California Public Employees Retirement System owned approximately 0.20% of Halozyme Therapeutics worth $4,430,000 as of its most recent SEC filing.
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.